Posts

Showing posts with the label Schizophrenia competitive landscape

Schizophrenia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Schizophrenia, a persistent and debilitating brain disorder, is typically characterized by two sets of symptoms: positive and negative. Those with schizophrenia often experience symptoms that leave them feeling fearful and withdrawn, with their speech and behavior becoming so disorganized that they can be incomprehensible or alarming to others. The ICD-10 outlines diagnostic criteria for seven subtypes of schizophrenia, which include Paranoid, Catatonic, Postschizophrenic Depression, Simple, Hebephrenic, Undifferentiated, and Residual schizophrenia. Schizophrenic disorders are thought to have a complex origin involving genetic, environmental, and neurotransmitter pathophysiological factors. Diagnosing schizophrenia involves psychiatric assessment since no definitive test exists for the condition. In the United States, diagnosis relies primarily on the Diagnostic and Statistical Manual (DSM-V), while in Europe, the International Classification of Diseases (ICD), 10th revision, is o...

Schizophrenia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Schizophrenia, a persistent and debilitating brain disorder, is typically characterized by two sets of symptoms: positive and negative. Those with schizophrenia often experience symptoms that leave them feeling fearful and withdrawn, with their speech and behavior becoming so disorganized that they can be incomprehensible or alarming to others. The ICD-10 outlines diagnostic criteria for seven subtypes of schizophrenia, which include Paranoid, Catatonic, Postschizophrenic Depression, Simple, Hebephrenic, Undifferentiated, and Residual schizophrenia. Schizophrenic disorders are thought to have a complex origin involving genetic, environmental, and neurotransmitter pathophysiological factors. Diagnosing schizophrenia involves psychiatric assessment since no definitive test exists for the condition. In the United States, diagnosis relies primarily on the Diagnostic and Statistical Manual (DSM-V), while in Europe, the International Classification of Diseases (ICD), 10th revision, is o...

Schizophrenia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Schizophrenia is a chronic, severe, and disabling brain disease. The symptoms of schizophrenia may leave afflicted persons fearful and withdrawn. Their speech and behavior can become so disorganized that they are incomprehensible or frightening to others. Available treatments can relieve many schizophrenic symptoms, but most people with schizophrenia continue to suffer some symptoms throughout their lives; it has been estimated that no more than one in five individuals recovers completely. schizophrenic disorders have a multifactorial etiology, with genetic, environmental, and neurotransmitter pathophysiological components. At present, there is no laboratory method that confirms a diagnosis of schizophrenia. There may or may not be a history of a major disruption in the person's life (failure, loss, physical illness) before gross psychotic deterioration is evident. ·        The annual incidence of Schizophrenia varies between 11 to 25 cases per ever...

Schizophrenia – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Image
  Schizophrenia is a chronic, severe, and disabling brain disease. The symptoms of schizophrenia may leave afflicted persons fearful and withdrawn. Their speech and behavior can become so disorganized that they are incomprehensible or frightening to others. Available treatments can relieve many schizophrenic symptoms, but most people with schizophrenia continue to suffer some symptoms throughout their lives; it has been estimated that no more than one in five individuals recovers completely. schizophrenic disorders have a multifactorial etiology, with genetic, environmental, and neurotransmitter pathophysiological components. At present, there is no laboratory method that confirms a diagnosis of schizophrenia. There may or may not be a history of a major disruption in the person's life (failure, loss, physical illness) before gross psychotic deterioration is evident. The annual incidence of Schizophrenia varies between 11 to 25 cases per every 100,000 population in the USA. The...